Circulating tumor DNA dynamics and pathologic response to neoadjuvant immunotherapy in resectable stage III melanoma.

e21560 Background: Pathologic response to neoadjuvant immunotherapy (NAI) can help predict recurrence in resectable stage III cutaneous melanoma. We investigated change in pre-surgery circulating tumor DNA (ctDNA) and its correlation with pathologic response and recurrence. Methods: We prospectively collected ctDNA at baseline, post-NAI (every 4-6 weeks), post-surgery in 21 resectable stage III melanoma patients who received NAI using Signatera at Inova Schar Cancer Institute. Following NAI, 6/21 (29%) achieved complete or near complete pathologic response (pCR/pnCR), 5/21 (24%) partial response (pPR), 10/21 (48%) non-response (pNR). At median follow up of 9 months, 3/10 (30%) patients with pNR recurred with a median time to recurrence of 11 months. None of pCR/pnCR/pPR recurred. Results: Baseline ctDNA was detectable in 14/21 (67%); 7 pNR, 7 non-pNR. Lack of post-NAI ctDNA clearance was observed in 6/7 (86%) pNR, while ctDNA clearance is observed in 7/7 (100%) non-pNR. Among pNR, post-NAI ctDNA decreased but never became 0 before surgery in 4/7 (57%) with one recurrence; increased without subsequent decrease in 2/7 (29%); not available in 1/7 (14%). Among non-pNR, post-NAI ctDNA was 0 in 3/7 (43%); increased with subsequent decrease in 3/7 (43%); increased without subsequent decrease in 1/7 (14%). Baseline ctDNA was 0 in 7/21 (33%). ctDNA remained 0 post-NAI and post-surgery in all of them with 2pCR/pnCR, 2pPR, 3pNR. Conclusions: Among patients with detected baseline ctDNA, lack of post-NAI ctDNA clearance prior to surgery may predict pNR. Larger study is needed to confirm this finding. Circulating tumor DNA dynamics and pathologic response. Baseline Post-NAI pCR/pnCR pPR pNR Total ctDNA detected ctDNA became 0 3 0 0 3 ctDNA increase then decrease 1 2 0 3 ctDNA increase without subsequent decrease 0 1 2 3 ctDNA decrease but not 0 0 0 4 (1 recurrence) 4 ctDNA not available 0 0 1(1 recurrence) 1 ctDNA not detected ctDNA remains 0 2 2 3 (1 recurrence) 7

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-05-28
DOI
https://doi.org/10.1200/jco.2025.43.16_suppl.e21560
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Circulating tumor DNA dynamics and pathologic response to neoadjuvant immunotherapy in resectable stage III melanoma.

Byung Min Yoo, Yu An, Sekwon Jang, Jafar Al-Mondhiry
1 links
Journal of Clinical Oncology
Immunotherapy and Immune Responses
article

Circulating tumor DNA dynamics and pathologic response to neoadjuvant immunotherapy in resectable stage III melanoma.

Byung Min Yoo, Yu An, Sekwon Jang, Jafar Al-Mondhiry
article en

Abstract

e21560 Background: Pathologic response to neoadjuvant immunotherapy (NAI) can help predict recurrence in resectable stage III cutaneous melanoma. We investigated change in pre-surgery circulating tumor DNA (ctDNA) and its correlation with pathologic response and recurrence. Methods: We prospectively collected ctDNA at baseline, post-NAI (every 4-6 weeks), post-surgery in 21 resectable stage III melanoma patients who received NAI using Signatera at Inova Schar Cancer Institute. Following NAI, 6/21 (29%) achieved complete or near complete pathologic response (pCR/pnCR), 5/21 (24%) partial response (pPR), 10/21 (48%) non-response (pNR). At median follow up of 9 months, 3/10 (30%) patients with pNR recurred with a median time to recurrence of 11 months. None of pCR/pnCR/pPR recurred. Results: Baseline ctDNA was detectable in 14/21 (67%); 7 pNR, 7 non-pNR. Lack of post-NAI ctDNA clearance was observed in 6/7 (86%) pNR, while ctDNA clearance is observed in 7/7 (100%) non-pNR. Among pNR, post-NAI ctDNA decreased but never became 0 before surgery in 4/7 (57%) with one recurrence; increased without subsequent decrease in 2/7 (29%); not available in 1/7 (14%). Among non-pNR, post-NAI ctDNA was 0 in 3/7 (43%); increased with subsequent decrease in 3/7 (43%); increased without subsequent decrease in 1/7 (14%). Baseline ctDNA was 0 in 7/21 (33%). ctDNA remained 0 post-NAI and post-surgery in all of them with 2pCR/pnCR, 2pPR, 3pNR. Conclusions: Among patients with detected baseline ctDNA, lack of post-NAI ctDNA clearance prior to surgery may predict pNR. Larger study is needed to confirm this finding. Circulating tumor DNA dynamics and pathologic response. Baseline Post-NAI pCR/pnCR pPR pNR Total ctDNA detected ctDNA became 0 3 0 0 3 ctDNA increase then decrease 1 2 0 3 ctDNA increase without subsequent decrease 0 1 2 3 ctDNA decrease but not 0 0 0 4 (1 recurrence) 4 ctDNA not available 0 0 1(1 recurrence) 1 ctDNA not detected ctDNA remains 0 2 2 3 (1 recurrence) 7

Journal of Clinical OncologyVol. 43(16_suppl)
Seoul National University Hospital (KR), Virginia Cancer Institute (US)
Openalex Percentile: Top 87%
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.